In other recent news, Savara Inc. has completed its Biologics License Application (BLA) submission to the U.S. Food and Drug Administration (FDA) for MOLBREEVI, a potential treatment for autoimmune ...

Savara Inc. (NASDAQ:SVRA), a biopharmaceutical company focused on developing novel therapies for rare respiratory diseases, is approaching a critical juncture in its journey to bring its lead ...

As the company completes its rolling Biologics License Application (BLA) submission for Molbreevi, investors and analysts are closely watching the potential first-in-class treatment for autoimmune ...

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Savara (SVRA – Research Report) and Zentalis Pharmaceuticals ...

Completed Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI * as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP ...

Matt Pauls, Chair and CEO of Savara, expressed optimism about the data supporting MOLBREEVI’s efficacy in improving pulmonary gas exchange and clinical symptoms of aPAP. Savara has requested a ...

"MOLBREEVI has the potential to be the first and only approved therapy for aPAP in the U.S. and Europe and could redefine the standard of care for the disease. If granted Priority Review ...